Does IQVIA (IQV) Data Push and Buybacks Reveal a New Phase in Its Strategy?

Simply Wall St.02-10

IQVIA Holdings reported fourth-quarter 2025 sales of US$4,364 million and full-year sales of US$16,310 million, alongside issuing 2026 revenue guidance of US$17,150 million to US$17,350 million that ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610695323?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/137473239-main-header/1756256222159","is_english":true,"pubTime":"2026-02-10 07:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610695323","market":"nz","top_or_hot":-1,"title":"Does IQVIA (IQV) Data Push and Buybacks Reveal a New Phase in Its Strategy?","media":"Simply Wall St.","content":"<div>\n<p>IQVIA Holdings reported fourth-quarter 2025 sales of US$4,364 million and full-year sales of US$16,310 million, alongside issuing 2026 revenue guidance of US$17,150 million to US$17,350 million that ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/does-iqvia-iqv-data-push-and-buybacks-reveal-a-new-phase-in\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does IQVIA (IQV) Data Push and Buybacks Reveal a New Phase in Its Strategy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes IQVIA (IQV) Data Push and Buybacks Reveal a New Phase in Its Strategy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-10 07:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/does-iqvia-iqv-data-push-and-buybacks-reveal-a-new-phase-in><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IQVIA Holdings reported fourth-quarter 2025 sales of US$4,364 million and full-year sales of US$16,310 million, alongside issuing 2026 revenue guidance of US$17,150 million to US$17,350 million that ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/does-iqvia-iqv-data-push-and-buybacks-reveal-a-new-phase-in\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0477156953.USD","symbol_name":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/does-iqvia-iqv-data-push-and-buybacks-reveal-a-new-phase-in","article_id":"2610695323","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/137473239-main-header/1756256222159"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/does-iqvia-iqv-data-push-and-buybacks-reveal-a-new-phase-in","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610695323","pubTimestamp":1770679615,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"IQVIA Holdings reported fourth-quarter 2025 sales of US$4,364 million and full-year sales of US$16,310 million, alongside issuing 2026 revenue guidance of US$17,150 million to US$17,350 million that factors in acquisition and foreign-exchange benefits.\nRecent moves, including a long-term Data-as-a-Service collaboration with Boehringer Ingelheim and ongoing share repurchases under a multi-year program, underline IQVIA’s push to deepen its role in data-driven healthcare decision-making.\nWe’ll...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","BK4588":"碎股","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","BK4121":"生命科学工具和服务","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","IQV":"艾昆纬","BK4585":"ETF&股票定投概念","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","BK4530":"医药外包概念","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC"},"translate_title":"IQVIA(IQV)的数据推送和回购是否揭示了其战略的新阶段？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IQV":1.5},"content_text":"IQVIA Holdings reported fourth-quarter 2025 sales of US$4,364 million and full-year sales of US$16,310 million, alongside issuing 2026 revenue guidance of US$17,150 million to US$17,350 million that factors in acquisition and foreign-exchange benefits. Recent moves, including a long-term Data-as-a-Service collaboration with Boehringer Ingelheim and ongoing share repurchases under a multi-year program, underline IQVIA’s push to deepen its role in data-driven healthcare decision-making. We’ll now examine how IQVIA’s new Boehringer Ingelheim data collaboration shapes the company’s broader investment narrative and future prospects. Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.AdvertisementWhat Is IQVIA Holdings' Investment Narrative?To own IQVIA, you need to believe in its role as a core data and services partner to global pharma, with durable demand for clinical execution and real-world data rather than one-off COVID-related momentum. The latest quarter and 2026 revenue guidance back up that “steady compounder” story, but the sharp share price pullback and only modest revenue growth expectations keep near term sentiment fragile. The new Boehringer Ingelheim Data-as-a-Service collaboration fits neatly into IQVIA’s push to be embedded in clients’ commercial decision-making, which could strengthen its data moat and underpin future contract wins, even if the impact on near term numbers is limited. At the same time, ongoing buybacks signal confidence but also magnify the existing leverage and cash flow coverage questions that equity holders now need to weigh more carefully. Despite retreating, IQVIA Holdings' shares might still be trading 38% above their fair value. Discover the potential downside here.Exploring Other PerspectivesIQV 1-Year Stock Price Chart The Simply Wall St Community’s four fair value views cluster between US$250 and about US$311, reminding you that independent investors can see meaningful upside even while recent earnings trends and debt coverage remain key swing factors for IQVIA’s longer term performance.Explore 4 other fair value estimates on IQVIA Holdings - why the stock might be worth just $250.00!Build Your Own IQVIA Holdings NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your IQVIA Holdings research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.Our free IQVIA Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IQVIA Holdings' overall financial health at a glance.Curious About Other Options?Our daily scans reveal stocks with breakout potential. Don't miss this chance:The latest GPUs need a type of rare earth metal called Neodymium and there are only 30 companies in the world exploring or producing it. Find the list for free.Find 52 companies with promising cash flow potential yet trading below their fair value.The future of work is here. Discover the 28 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610695323","isCrawlerRequest":true}